LSAQ - LifeSci Acquisition Corp. pops 4.5% on SPAC deal to take Science 37 public at $1.1B valuation

LifeSci Acquisition II Corp. (LSAQ) popped nearly 5% Friday after announcing plans to take drug-trials platform Science 37 public through a SPAC deal that values the firm at about $1.1B.LSAQ’s shares rose to as high as $10.57 in early trading, up 4.5% on the session. Shares later pulled back slightly, but were changing hands at $10.54 shortly before 10:30 a.m. ET, up 4.3% on the day.Science 37 operates a platform to help pharmaceutical and biotech companies and academic and governmental researchers conduct drug trials. The company assists in enrolling patients in trials, and also coordinates in-site, off-site and virtual visits with doctors and mobile nurses to treat and retain study participants.Since its 2014 founding, Science 37 has conducted more than 95 decentralized clinical trials involving more than 366,000 patients.“Healthcare is increasingly transitioning to virtual and home-based environments, and we believe Science 37 is uniquely positioned as a pioneer in its

For further details see:

LifeSci Acquisition Corp. pops 4.5% on SPAC deal to take Science 37 public at $1.1B valuation